Dublin, Ireland-headquartered Horizon Pharma has now completed the acquisition of US group Raptor Pharmaceutical.
Under the deal, Horizon has acquired all of issued and outstanding shares of Raptor common stock for $9.00 per share in cash, which equates to around $800 million in total.
According to Horizon, the deal strengthens its focus on rare diseases and provides expansion into Europe and other international markets, and diversifies revenue with 11 medicines across three business units orphan, rheumatology and primary care.
“The acquisition of Raptor directly aligns with our long-term strategy and evolution into a rare disease focused company, where now more than half of our medicines are used to treat patients with rare diseases,” said Timothy P. Walbert, chairman, president and chief executive of Horizon.
“The added infrastructure in Europe and other key international markets will further benefit the access to both our current and newly acquired medicines as well as position us for the potential introduction of Actimmune for Friedreich’s ataxia in Europe in future years if the results of the Phase III trial are positive.”
The deal is expected to be accretive to adjusted EBITDA in 2017.
By Selina McKee
Source: Pharma Times
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
